Frontiers in Neurology (Apr 2019)
Platelet Count Predicts Adverse Clinical Outcomes After Ischemic Stroke or TIA: Subgroup Analysis of CNSR II
- Ming Yang,
- Ming Yang,
- Ming Yang,
- Ming Yang,
- Yuesong Pan,
- Yuesong Pan,
- Yuesong Pan,
- Yuesong Pan,
- Zixiao Li,
- Zixiao Li,
- Zixiao Li,
- Zixiao Li,
- Hongyi Yan,
- Hongyi Yan,
- Hongyi Yan,
- Hongyi Yan,
- Xingquan Zhao,
- Xingquan Zhao,
- Xingquan Zhao,
- Xingquan Zhao,
- Liping Liu,
- Liping Liu,
- Liping Liu,
- Liping Liu,
- Jing Jing,
- Jing Jing,
- Jing Jing,
- Jing Jing,
- Xia Meng,
- Xia Meng,
- Xia Meng,
- Xia Meng,
- Yilong Wang,
- Yilong Wang,
- Yilong Wang,
- Yilong Wang,
- Yongjun Wang,
- Yongjun Wang,
- Yongjun Wang,
- Yongjun Wang
Affiliations
- Ming Yang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Ming Yang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Ming Yang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Ming Yang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Yuesong Pan
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Yuesong Pan
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Yuesong Pan
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Yuesong Pan
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Zixiao Li
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Zixiao Li
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Zixiao Li
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Zixiao Li
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Hongyi Yan
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Hongyi Yan
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Hongyi Yan
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Hongyi Yan
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Xingquan Zhao
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Xingquan Zhao
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Xingquan Zhao
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Xingquan Zhao
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Liping Liu
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Liping Liu
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Liping Liu
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Liping Liu
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Jing Jing
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Jing Jing
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Jing Jing
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Jing Jing
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Xia Meng
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Xia Meng
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Xia Meng
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Xia Meng
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Yilong Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Yilong Wang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Yilong Wang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Yilong Wang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- Yongjun Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Fengtai District, China
- Yongjun Wang
- China National Clinical Research Center for Neurological Diseases, Beijing, China
- Yongjun Wang
- Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
- Yongjun Wang
- Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
- DOI
- https://doi.org/10.3389/fneur.2019.00370
- Journal volume & issue
-
Vol. 10
Abstract
Background: The clinical significance of platelet count (PC) for ischemic cerebrovascular disease is not well-established and further risk stratification according to baseline PC within normal range has not been reported before. We aim to evaluate the prognostic effect of baseline circulating PC within normal range on the risk of long-term recurrent stroke, mortality and functional outcomes after ischemic stroke or TIA.Methods: We derived data from eligible patients with ischemic stroke or TIA from the China National Stroke Registry (CNSR) II. Participants were divided into quintiles according to baseline PC within normal range (100–450 × 109/L). Multivariable cox regression and logistic regression were adopted to explore the correlation of baseline PC with recurrent stroke, mortality and poor functional outcomes (modified Rankin Scale 3~6) within 1-year follow-up.Results: Among the16842 eligible participants, the average age was 64.7 ± 11.9, 1,241 (7.4%) had recurrent stroke, 1,377 (8.2%) died, and 3,557 (21.1%) ended up with poor functional outcomes after 1-year follow-up. Compared with the third PC quintile (186–212 × 109/L), patients in the top quintile (249–450 × 109/L) presented with increased risk of recurrent stroke (adjusted hazard ratio 1.21, [1.02–1.45]), all-cause mortality (adjusted hazard ratio 1.43, [1.19–1.73]), and poor functional outcome (adjusted odds ratio 1.49, [1.28–1.74]), while patients in the lowest PC quintile(100–155 × 109/L) had higher risk of poor functional outcome (adjusted odds ratio 1.19, [1.02–1.38]).Conclusion: In ischemic stroke or TIA patients with platelet count within normal range, platelet count may be a qualified predictor for long-term recurrent stroke, mortality, and poor functional outcome.
Keywords